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Abnormal involuntary movements (AIMs) and dyskinesias elicited by drugs that stimulate
dopamine receptors in the basal ganglia are a major issue in the management
of Parkinson’s disease (PD). Preclinical studies in dopamine-denervated animals
have contributed to the modeling of these abnormal movements, but the precise
neurochemical and functional mechanisms underlying these untoward effects are still
elusive. It has recently been suggested that the performance of movement may itself
promote the later emergence of drug-induced motor complications, by favoring the
generation of aberrant motor memories in the dopamine-denervated basal ganglia.
Our recent results from hemiparkinsonian rats subjected to the priming model of
dopaminergic stimulation are in agreement with this. These results demonstrate that
early performance of movement is crucial for the manifestation of sensitized rotational
behavior, indicative of an abnormal motor response, and neurochemical modifications in
selected striatal neurons following a dopaminergic challenge. Building on this evidence,
this paper discusses the possible role of movement performance in drug-induced motor
complications, with a look at the implications for PD management.
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Motor complications induced by dopamine replacement therapy
(DRT) are the major untoward effects associated with the phar-
macologic management of Parkinson’s disease (PD). These com-
plications include end-of-dose deterioration, motor fluctuations,
and abnormalmotor responses, the latter being very disabling and
severely limiting the patient’s quality of life. Results obtained in
experimental animal models of PD have indicated that pulsatile
stimulation of dopamine receptors following DRT is a key step
in the emergence of abnormal motor responses, and that these
untoward effects are associated with a malfunction in the sig-
nal transduction pathway of the dopamine D1 receptor (Gerfen
et al., 1990; Nutt, 2007; Santini et al., 2008; Guigoni and Bezard,
2009; Stocchi, 2009). Nevertheless, the precise mechanisms that
underlie abnormal motor responses caused by DRT are still to be
elucidated.
Recent findings have suggested that the generation of aberrant
procedural memories in striatal motor circuits could participate
in the manifestation of abnormalmotor responses associated with
DRT (Calon et al., 2000; Pisani et al., 2005; Jenner, 2008; Simola
et al., 2009; Frau et al., 2013). Thus, the striatum plays a major
role in processes such as integration of motor signals, acquisition
of motor habits, and execution of motor programs, which are
all critically regulated by dopamine (Mink, 1996; Packard and
Knowlton, 2002; Gerdeman et al., 2003; Tang et al., 2007; Willuhn
and Steiner, 2008). Starting from these premises, it has been
hypothesized that the dopamine-denervated striatum fails to
properly process motor information, and that this may result in
an overload of striatal motor circuits following the performance
of movement stimulated by drugs that activate dopamine
receptors (Picconi et al., 2005; Pisani et al., 2005). This process, in
turn, would promote pathologic motor learning, and eventually
the onset of abnormal motor responses, such as dyskinesia
(Picconi et al., 2005; Jenner, 2008). Therefore, the performance of
movement might itself play a role in the emergence of abnormal
motor responses caused by DRT. Interestingly, studies in both
dopamine-denervated experimental animals and PD patients
provide support to this view, by showing that physical activity
may influence the severity of abnormal motor responses triggered
by repeated administration of dopaminergic drugs (Reuter et al.,
1999, 2000; Frazzitta et al., 2012; Aguiar et al., 2013). Moreover,
recent evidence obtained in an experimental model of abnormal
motor responses in hemiparkinsonian rats has provided a direct
demonstration of an important role of movement performance
in the emergence of these untoward effects (Simola et al., 2009;
Frau et al., 2013).
CRITICAL EVALUATION OF ABNORMAL MOTOR RESPONSES
IN EXPERIMENTAL ANIMAL MODELS OF PD
Studies in experimental animals have dramatically contributed to
the modeling of abnormal motor responses induced by dopamin-
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ergic drugs and elucidation of their mechanisms, and important
results in this sense have been obtained in the unilaterally 6-
hydroxydopamine (6-OHDA)-lesioned rat. Briefly, this animal
model is characterized by a hemiparkinsonism subsequent to
the infusion of 6-OHDA in the nigrostriatal pathway, which
manifests as unilateral forelimb akinesia (Simola et al., 2007).
Moreover, when treated with drugs that stimulate dopamine
receptors, 6-OHDA-lesioned rats display a characteristic con-
tralateral rotational behavior directed away from the site of toxin
infusion, which is indicative of the antiparkinsonian effectiveness
of the drug (Deumens et al., 2002; Simola et al., 2007). How-
ever, it is worth emphasizing that the repeated administration of
drugs that stimulate dopamine receptors induces a sensitization
in contralateral rotational behavior which reproduces the same
biochemical changes observed in rats displaying dyskinetic-like
abnormal involuntary movements (AIMs). In fact, abnormal
motor responses induced by repeated treatment with dopaminer-
gic drugs can be modeled in 6-OHDA-lesioned rats by measuring
two types of behaviors: AIMs and sensitization in contralateral
rotational behavior. AIMs consist of repetitive and purposeless
movements of limbs and trunk, and are a reliable rodent model
of human dyskinesias (Cenci et al., 1998; Lindgren et al., 2007).
Sensitization in contralateral rotational behavior is also indicative
of abnormal motor responses to dopaminergic drugs, since the
intensity of this phenomenon directly correlates with the pro-
dyskinetic potential of these drugs (Henry et al., 1998; Pinna et al.,
2006; Carta et al., 2008).
With regard to sensitization in contralateral rotational behav-
ior, it is worth mentioning the priming model. Priming involves
a first administration of a dopamine D1/D2 receptor agonist
(induction phase) that stimulates contralateral rotational behav-
ior, followed, 3 days later, by the administration of a highly
dyskinetic D1 receptor agonist (expression phase), at otherwise
scarcely effective doses on rotational behavior (Morelli et al.,
1989). Primed hemiparkinsonian rats display a vigorous con-
tralateral rotational behavior on the expression phase, which is
associated with neurochemical modifications in the striatum that
are peculiar to experimental paradigms of prolonged admin-
istration of dopaminergic drugs (Pollack et al., 1997; van de
Witte et al., 1998; Simola et al., 2007; Scholz et al., 2008; Nadjar
et al., 2009). This evidence, therefore, indicates that the priming
model is highly valuable for investigating the mechanisms that
underlie abnormal motor responses to dopaminergic drugs in
hemiparkinsonian rats.
MOVEMENT PERFORMANCE FOLLOWING INITIAL
DOPAMINERGIC STIMULATION ENABLES THE
MANIFESTATION OF SENSITIZED ROTATIONAL
BEHAVIOR IN PRIMED HEMIPARKINSONIAN RATS
Hemiparkinsonian 6-OHDA-lesioned drug-naïve rats that are
treated with the D1/D2 agonist apomorphine (0.2 mg/kg, s.c.)
during priming induction and left to rotate freely in response to
the drug exhibit a marked contralateral rotational behavior when
challenged 3 days later with the D1 receptor agonist 1-Phenyl-
2,3,4,5-tetrahydro-(1H)-3-benzazepine-7,8-diol (SKF 38393, 3
mg/kg, s.c.), which is indicative of an abnormal motor response
(Morelli et al., 1989; Simola et al., 2009). This behavioral effect
of SKF 38393 has been found to be almost completely abolished
in rats subjected to the same pharmacologic treatment that
were immobilized for 1 h in a restrainer apparatus during
priming induction, so that they could not perform rotational
behavior in response to apomorphine (Figure 1; Simola et al.,
2009). Importantly, immobilization has been demonstrated to
suppress priming expression only when imposed concomitantly
to apomorphine administration, but not immediately before
or immediately after priming induction, therefore excluding
a non-specific effect of immobilization (Simola et al., 2009).
Moreover, the influence of immobilization on the effects of SKF
38393 has been shown not to be affected by the elevation in stress
hormones that is associated with this procedure. This is clearly
demonstrated by the finding that immobilization during priming
induction retained the suppressant effects on priming expression
even in rats treated with metyrapone (Simola et al., 2009), which
prevents the elevation in stress glucocorticoid hormones that
may be caused by immobilization (Calvo and Volosin, 2001).
This finding is very important, since previous evidence has
demonstrated that stress may have a profound influence on the
behavioral and neurochemical effects of movement performance
(Howells et al., 2005). Taken together, these findings indicate
that the suppression of priming expression in rats immobilized
during priming induction is attributable solely to the fact that
immobilization prevented rats from performing movement in
FIGURE 1 | Magnitude of contralateral rotational behavior stimulated
by acute SKF 38393 (3 mg/kg s.c.) in primed rats, recorded for 2 h.
Priming induction was performed with apomorphine (0.2 mg/kg s.c.), and
was followed by priming expression with SKF 38393 (3 mg/kg s.c.), 3 days
later. Rats were either allowed to rotate or were immobilized during priming
induction. *p < 0.05 vs. non-primed rats and primed immobilized rats.
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response to the initial dopaminergic stimulation (Simola et al.,
2009). Therefore, the results obtained in hemiparkinsonian
rats subjected to the priming model have provided the first
direct demonstration that the performance of drug-stimulated
movement may be crucial for the later emergence of abnormal
motor responses to repetitive administration of dopaminergic
drugs.
MOTOR PERFORMANCE FOLLOWING INITIAL
DOPAMINERGIC STIMULATION TRIGGERS
NEUROCHEMICAL MODIFICATIONS IN SELECTED STRIATAL
EFFERENT NEURONS OF PRIMED HEMIPARKINSONIAN RATS
In order to evaluate whether or not movement performance trig-
gers changes indicative of neuronal long-term modifications, sev-
eral biochemical and molecular parameters have been evaluated
in the striatum of hemiparkinsonian drug-naïve and primed rats.
The results obtained have demonstrated that both sensitized rota-
tional behavior on the expression of priming and dyskinetic-like
movements in dopamine-denervated animals repeatedly treated
with dopaminergic drugs are associated with long-term changes
in the production of striatal cyclic adenosine monophosphate
(cAMP; Pinna et al., 1997), phosphorylation of dopamine- and
cAMP-regulated neuronal phosphoprotein (DARPP-32; Santini
et al., 2007), and expression of mRNAs encoding for different pro-
teins and immediate early genes (IEGs; Barone et al., 1994; Cenci
et al., 1998, 2009; Crocker et al., 1998; van de Witte et al., 1998;
Carta et al., 2003, 2008; Aubert et al., 2005). In this regard, the IEG
zif-268 has recently been shown to be a useful marker of neuronal
modification that involves striatal efferent pathways in animal
models of abnormal motor responses (Carta et al., 2008, 2010).
zif-268 (also known as Egr-1, Krox-24, NGFI-A, or Zenk)
belongs to a class of inducible IEGs that encode regulatory tran-
scription factors, and that have been implicated in diverse pro-
cesses in a variety of cell types, including cell growth, differenti-
ation, and apoptosis in response to extracellular stimuli (Gashler
and Sukhatme, 1995). In the brain, zif-268 mRNA and protein
are constitutively expressed in several areas, such as the neocortex
and hippocampus, and, of great importance in PD, the striatum
(Christy et al., 1988; Mack et al., 1990; Schlingensiepen et al.,
1991; Worley et al., 1991). Moreover, zif-268 can be rapidly and
transiently induced by a variety of pharmacologic and physiologic
stimuli, including neurotransmitters, growth factors, peptides,
depolarization, seizures, ischemia, and brain injury or cellular
stress (Gashler and Sukhatme, 1995; Beckmann and Wilce, 1997).
As mentioned above, zif-268 may represent a useful and sensi-
tive neurochemical marker in the evaluation of abnormal motor
and neuronal responses associated with the onset of dyskine-
sia in dopamine-denervated animals treated with dopaminergic
drugs (Carta et al., 2005, 2008). Thus, drugs such as L-3,4-
dihydroxyphenylalanine (L-DOPA) and SKF 38393, which induce
severe dyskinetic-like movements, markedly increase the levels
of zif-268 mRNA in striatal neurons, after both acute and sub-
chronic treatment (Carta et al., 2005, 2008, 2010). In contrast,
treatment with drugs that elicit a scarce dyskinetic-like response,
such as ropinirole, do not produce any elevation in zif-268 (Carta
et al., 2010). Notably, the expression of mRNA encoding for zif-
268 was selectively increased in the direct striatonigral pathway,
which seems to be the pathway most involved in development of
dyskinetic movements (Carta et al., 2010).
Similar to these findings, experiments in 6-OHDA-lesioned
hemiparkinsonian rats subjected to the priming model have
shown that the administration of the D1 receptor agonist
SKF 38393 on priming expression induces an increase in striatal
zif-268mRNA (Frau et al., 2013). Moreover, analysis at the single-
cell level showed that only enkephalin(−) striatonigral neurons,
which belong to the direct pathway, displayed a significantly
higher expression of zif-268 following SKF 38393. On the other
hand, enkephalin(+) striatopallidal neurons, which belong to
the indirect pathway, that is less involved in abnormal motor
responses elicited by dopaminergic drugs (Carta et al., 2010), did
not show any significant modifications in the levels of zif-268.
No significant differences in this effect were observed when the
results from primed rats that performed rotational behavior
during priming induction were compared with those obtained
in rats that were immobilized on priming induction (Frau et al.,
2013). This latter finding seems to suggest that modifications in
zif-268 mRNA levels observed in the enkephalin(−) striatonigral
neurons of hemiparkinsonian rats during priming expression
are not influenced by the fact that the rats could perform
rotational behavior during priming induction. In this regard, it
is worth mentioning that enkephalin(−) striatopallidal neurons
include two subpopulations: substance P(+) and dynorphin(+)
neurons. Analysis of zif-268 in these neuronal populations has
demonstrated a selective increase of this IEG in dynorphin(+)
striatonigral neurons of rats primed with SKF 38393 that
performed rotational behavior during priming induction,
compared with primed rats immobilized on priming induction
(Figure 2). This finding demonstrates, in the first place, a
critical role of drug-stimulated movement performance in the
emergence of neurochemical modifications in striatal neurons of
dopamine-denervated rats subjected to repetitive administration
of dopaminergic drugs, and that the dynorphin(+) neurons are
selectively involved in the long-term modifications caused by
early motor performance in the priming model (Frau et al.,
2013). Moreover, the intensity of rotational behavior on priming
expression was found to correlate positively with the levels of
zif-268 mRNA in dynorphin(+) neurons (Frau et al., 2013). This
finding is very interesting, as it indicates a relationship between
early performance of drug-stimulated movement and appearance
of neurochemical adaptations associated with an abnormalmotor
response to dopaminergic drugs (Frau et al., 2013).With regard to
the modifications in the levels of zif-268 in the priming model, it
is also relevant to observe that zif-268 is rapidly induced in certain
forms of learning, or after long-term potentiation (Lanahan and
Worley, 1998; O’Donovan et al., 1999; Tischmeyer and Grimm,
1999; Bozon et al., 2002), and has recently been shown to be
necessary for the formation of different forms of long-term
memory (Jones et al., 2001). Together with the results obtained
in the priming model, this finding would provide support to
the hypothesis suggesting that abnormal motor responses to
repetitive administration of dopaminergic drugs in conditions
of dopaminergic denervation might involve the generation of
abnormal procedural memories in striatal motor circuits.
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FIGURE 2 | Photomicrograph and histogram showing zif-268 mRNA
expression as number of silver grains/neuron in dynorphin(+)
striatonigral neurons from the 6-OHDA-lesioned dorsolateral striatum
of rats subjected to priming. Priming induction was performed with
apomorphine (0.2 mg/kg s.c.), and was followed by priming expression with
SKF 38393 (3 mg/kg s.c.), 3 days later. Rats were either allowed to rotate or
were immobilized during priming induction. Rats were sacrificed 2 h after
SKF 38393 administration to perform in situ hybridization studies. *p < 0.05
vs. non-primed rats and primed immobilized rats.
CONCLUSIONS
The results obtained in 6-OHDA-lesioned hemiparkinsonian
rats subjected to the priming model demonstrate that the
early performance of drug-stimulated movement promotes
the later emergence of an abnormal motor response and
striatal neurochemical adaptations following the subsequent
administration of dopaminergic drugs with pro-dyskinetic
potential (Simola et al., 2009; Frau et al., 2013). These results may
appear to contrast with recent studies in experimental animals
and PD patients that demonstrate how performance ofmovement
in the form of physical training and exercise may improve motor
deficits and even ameliorate dyskinesias (Goodwin et al., 2008;
Döbrössy et al., 2010; Frazzitta et al., 2010; Dutra et al., 2012;
Frazzitta et al., 2012; Aguiar et al., 2013). In this regard, it is
worth considering that extensive neuroplasticity takes place in the
striatum, which regulates movement performance, that physical
activity may interfere with these neuroplastic phenomena,
eventually influencing the execution of movement at a later time,
and that neuroplasticity can be profoundlymodified in conditions
of dopamine denervation (Tillerson et al., 2001; Packard and
Knowlton, 2002; Smith and Zigmond, 2003; Schouenborg,
2004; Graybiel, 2005). Therefore, it can be hypothesized that
drug-stimulated movement and voluntary physical activity,
given their different nature, might result in distinct neuroplastic
adaptations in the dopamine-denervated striatum, leading to
different effects on abnormalmotor responses. Thus, irrepressible
movement stimulated by dopaminergic drugs could overload
striatal motor circuits with redundant information and promote
pathologic motor learning, eventually triggering the generation
of aberrant habits, which may manifest as abnormal motor
responses, such as dyskinesias (Calon et al., 2000; Picconi et al.,
2005; Jenner, 2008). On the other hand, physical activity in
the framework of therapeutic programs could compete with
purposeless movements triggered by dopaminergic drugs,
therefore counteracting the generation of abnormal procedural
mnemonic traces in the striatum, and thus ameliorating motor
performance and mitigating dyskinesias.
In summary, the results obtained in hemiparkinsonian rats
subjected to the priming model suggest that the performance
of movement in response to an initial stimulation of dopamine
receptors in the dopamine-denervated striatum plays a key role
in the emergence of both abnormal motor responses and specific
neuroadaptive changes in response to a later dopaminergic chal-
lenge. These results may help understand the initial molecular
events that are at the basis of motor complications, such as
dyskinesia, associated with DRT used to manage PD.
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